Sugi Predict

Sugi Predict / Compounds / SCHEMBL14014144

SCHEMBL14014144

SCHEMBL14014144

Cc1ccc(NC(=O)[C@H]2C[C@@H]2c2ccccc2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DEGS1 O15121 1/20 0.76
▸ ALDH1A1 P00352 6/20 0.69
▸ SMN1; SMN2 Q16637 3/20 0.69
▸ NAMPT P43490 2/20 0.69
▸ LMNA P02545 2/20 0.69
▸ GAA P10253 1/20 0.69
▸ HTT P42858 1/20 0.69
▸ SCN3A Q9NY46 1/20 0.64
▸ TDP1 Q9NUW8 2/20 0.63
▸ NPC1 O15118 3/20 0.60
▸ RAB9A P51151 2/20 0.60
▸ HDAC4 P56524 1/20 0.59
▸ CYP1A2 P05177 1/20 0.59
▸ CYP3A4 P08684 1/20 0.59
▸ CYP2C9 P11712 1/20 0.59
▸ CYP2C19 P33261 1/20 0.59
▸ MEN1 O00255 2/20 0.57
▸ HPGD P15428 2/20 0.57
▸ KMT2A Q03164 2/20 0.57
▸ MAPT P10636 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2233174 1.00 DEGS1 (0.76) DEGS1ALDH1A1SMN1; SMN2NAMPTLMNA
SCHEMBL26373212 0.94 DEGS1 (0.67) DEGS1ALDH1A1SMN1; SMN2NAMPTLMNA
SCHEMBL26373196 0.92 ALDH1A1 (0.72) DEGS1ALDH1A1SMN1; SMN2NAMPTLMNA
SCHEMBL15706299 0.89 DEGS1 (0.82) DEGS1ALDH1A1SMN1; SMN2NAMPTLMNA
SCHEMBL20284023 0.87 DEGS1 (0.74) DEGS1ALDH1A1SMN1; SMN2NAMPTLMNA
SCHEMBL21522275 0.86 DEGS1 (1.00) DEGS1ALDH1A1SMN1; SMN2NAMPTLMNA
SCHEMBL20284448 0.86 DEGS1 (1.00) DEGS1ALDH1A1SMN1; SMN2NAMPTLMNA
SCHEMBL15560342 0.85 DEGS1 (0.76) DEGS1ALDH1A1SMN1; SMN2NAMPTLMNA
SCHEMBL20707736 0.85 DEGS1 (0.76) DEGS1ALDH1A1SMN1; SMN2NAMPTLMNA
SCHEMBL16845366 0.85 DEGS1 (0.76) DEGS1ALDH1A1SMN1; SMN2NAMPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080287466-A1 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF ADAMS JERRY LEROY 2008-11-20 — — US disclosed
US-20080287466-A1 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF ADAMS JERRY LEROY 2008-11-20 — — US disclosed
US-7427623-B2 4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and pharmacetical compositions thereof SMITHKLINE BEECHAM CORPORATION (US) 2008-09-23 — — US disclosed
US-7427623-B2 4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and pharmacetical compositions thereof SMITHKLINE BEECHAM CORPORATION (US) 2008-09-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287466-A1 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF TIE1, TEK, KDR DEGS1 3763/4885ALDH1A1 1144/4885SMN1; SMN2 3836/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.